Article Details

Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial

Retrieved on: 2021-09-15 13:52:30

Tags for this article:

Click the tags to see associated articles and topics

Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial. View article details on HISWAI: https://www.fiercepharma.com/pharma/citing-less-than-optimal-outcomes-for-roche-s-evrysdi-some-patients-biogen-launches-high

Excerpt

Biogen said it plans to launch a trial to test a high dose of Spinraza in patients who've had prior treatment with a rival from Roche. (Biogen).

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up